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Direct oral anticoagulants targeting specific coagulation factors have been introduced as alternatives to conventional
anticoagulants for both prophylactic and therapeutic indications. They have succeeded in overcoming the limitations of
vitamin K antagonists.
Although the favourable efficacy and side-effect profiles
compared to vitamin K antagonists is proven, there is significant concern about management of hemorrhage under
direct oral anticoagulants. There is no specific antidote or
method for reversing the antithrombotic effect of these drugs
available, at present. Most of the management of hemorrhage
is based on expert opinion and case reviews. Specific treatment regimens are needed to avoid consequences of acute
hemorrhage while patients are on anticoagulation. Therefore,
the focus of this special issue is to define a management
system for oral anticoagulants in the peri- and postoperative
setting.
Moreover, the long-term safety in clinical routine life
of direct oral anticoagulants is not well-known. One study
performed in clinical practice included a small cohort of
patients with acute cerebral hemorrhage starting dabigatran
etexilate for secondary stroke prevention to investigate efficacy and safety of this drug for one year. Another point
which has to be considered for treatment with direct oral
anticoagulants depends on the cost-effectiveness. In this issue
a comparison of the cost-utility analysis between edoxaban,
dabigatran, rivaroxaban, and apixaban in German population
is described.

Due to the heterogeneous mode of action and pharmacokinetic profile, each direct oral anticoagulant will vary in
its effects on laboratory assays, and to avoid mismanagement
clinicians are placed in a difficult position. One review published in this issue provides an overview of current knowledge
regarding appropriate coagulation assays to measure the
pharmacodynamics of the direct oral anticoagulants.
For this special issue we have also invited investigators
to contribute original research articles that continue the
development of strategies performed by the direct oral
anticoagulants. The synthesis of a novel compound, trehalose
octasulfate, is presented that employs a multitarget strategy
to modulate the activity of various components of thrombus
formation.
Good quality observational studies and data analyses
are often sufficient to provide a guide for better treatment
with drugs as the new anticoagulants. Different models of
anticoagulation treatment might have different impacts on
patients’ satisfaction. However, more investigation is needed
on the management of the target-specific oral anticoagulants.
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